Abstract Library

#4562 Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: The OCLURANDOM trial

Introduction: No published randomised trial investing the role of PRRT (177Lutetium-DOTA-Octreotate) in advanced progressive PaNET patients.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Walter T, Beron A, Smith D, Deandreis D,

Keywords: Pancreatic neuroendocrine, randomised phase 2 trial, Lutathera, Sunitinib,

#4096 Co-production of patient information: A model for today’s practice

Introduction: According to the British Medical Association, good quality patient information is fundamental to effective, patient-centred, quality care. It rightly considers patients as partners in their care, “Co-production involves engaging groups of people who use healthcare services, in equal partnership; at the earliest stages of service design, development and evaluation. It acknowledges that people with ‘lived experience’ of a particular condition are often best placed to advise on what support and services will make a positive difference to their lives.” (NHS England) The re-introduction of a liver transplantation programme in the UK for selected patients with a Neuroendocrine Neoplasm offers new opportunities to improve survival and quality of life: good quality information is a key tool for informed consent.

Conference:

Presenting Author:

Authors: Jervis N, Ellis C, Smith S, Shah T, Lewis K,

Keywords: Liver Transplantation, Co-production, Patient Information, Lived Experience Contribution,

#3875 Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with Holmium-166 radioembolization

Introduction: Radioembolization is a viable treatment option for neuroendocrine liver metastases.

Conference:

Presenting Author: Ramdhani K

Authors: Ramdhani K, Verduin J, Smits M, Bruijnen R, Lam M,

Keywords: Radioembolization, SIRT, holmium-166, neuroendocrine liver metastasis,

#3575 Claudin 18 immunohistochemistry for determining site of origin of metastatic neuroendocrine tumor

Introduction: Claudin 18 isoform 2 (CLDN18.2) is selectively expressed in normal and neoplastic gastric tissue and some pancreatic neoplasia. Anti-CLDN18.2 is an investigational therapy in gastric and pancreatic adenocarcinoma and a sensitive and specific immunohistochemical marker in these cancers.

Conference:

Presenting Author: Smith B

Authors: Smith B, Rice K, Setthavongsack N, Woltjer R, Wong M,

Keywords: neuroendocrine, immunohistochemistry, claudin 18, CLDN18, gastric,

#3542 Essential role of nutritional support in patients with advanced carcinoid heart disease

Introduction: Chronic heart failure leads to cachexia in 5-15% of patients. Malnutrition affects 58% of patients with carcinoid syndrome.

Conference:

Presenting Author:

Authors: Shah H, Mair R, Arif S, Smith S, Vickrage S,

Keywords: carcinoid syndrome, carcinoid heart disease, nutrition, nasogastric feeding,